MedPath

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Phase 2
Conditions
Lymphoma
Registration Number
NCT00030589
Lead Sponsor
Millennix
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs, such as methoxsalen, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. Combining chemotherapy with photodynamic therapy may be an effective treatment for cutaneous T-cell lymphoma.

PURPOSE: Randomized phase II trial to study the effectiveness of combining different doses of bexarotene with photodynamic therapy in treating patients who have stage IB or stage IIA cutaneous T-cell lymphoma.

Detailed Description

OBJECTIVES:

* Compare the efficacy of 2 different doses of bexarotene administered with ultraviolet A light therapy with methoxsalen (PUVA) in patients with stage IB or IIA cutaneous T-cell lymphoma.

* Compare the safety of these regimens in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to one of two treatment arms.

* Arm I: Patients receive a lower dose of oral bexarotene once daily on weeks 1-26. Patients also receive ultraviolet A light therapy with oral methoxsalen 3 times weekly on weeks 2-26.

* Arm II: Patients receive a higher dose of oral bexarotene once daily on weeks 1-26. Patients also receive ultraviolet A light therapy as in arm I.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (17)

University of Alabama at Birmingham Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

University of Arkansas for Medical Sciences

πŸ‡ΊπŸ‡Έ

Little Rock, Arkansas, United States

Stanford University Medical Center

πŸ‡ΊπŸ‡Έ

Stanford, California, United States

University of Colorado Health Science Center

πŸ‡ΊπŸ‡Έ

Aurora, Colorado, United States

H. Lee Moffitt Cancer Center and Research Institute

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Northwestern University Medical Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Rush-Presbyterian-St. Luke's Medical Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Tulane University School of Medicine

πŸ‡ΊπŸ‡Έ

New Orleans, Louisiana, United States

Boston Medical Center

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute

πŸ‡ΊπŸ‡Έ

Detroit, Michigan, United States

Scroll for more (7 remaining)
University of Alabama at Birmingham Comprehensive Cancer Center
πŸ‡ΊπŸ‡ΈBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.